Draig Therapeutics

Executive Summary

Draig Therapeutics is a private UK-based biotech company focused on developing next-generation neuromodulators for neuropsychiatric disorders. Founded in 2020 and headquartered in Cambridge, the company aims to redefine the treatment paradigm for conditions such as depression, anxiety, and schizophrenia by targeting specific neural circuits with improved precision and reduced side effects. Draig's pipeline is currently in Phase 2, indicating that its lead candidate has progressed through early clinical safety and efficacy testing. The company's approach leverages advanced understanding of neurobiology to create highly targeted small molecules that modulate key neurotransmitter systems. With a strong scientific foundation and a clear unmet medical need, Draig is positioned to address the limitations of current therapies, which often have delayed onset or significant adverse effects. The company's progress to Phase 2 suggests that its lead asset has demonstrated favorable safety and initial efficacy signals, warranting further investment and development. As neuropsychiatric disorders represent a large and growing market, Draig's novel approach could offer significant value if clinical data continue to be positive.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Top-Line Data Readout for Lead Asset50% success
• Q4 2026Strategic Partnership or Licensing Deal40% success
• Q1 2027Series B Financing Round70% success